FTISADTSK (acetate)
FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) [1].
Product Specifications
UNSPSC
12352209
Target
Drug Metabolite
Type
Peptides
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ftisadtsk-acetate.html
Purity
99.66
Solubility
H2O : 50 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)[C@H]([C@@H](C)CC)NC([C@H]([C@H](O)C)NC([C@@H](N)CC1=CC=CC=C1)=O)=O.CC(O)=O
Molecular Formula
C44H72N10O18
Molecular Weight
1029.10
References & Citations
[1]Bults P, et al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016;88 (3) :1871-1877.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog